Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889003 | 0.77 | CYP1A2 (0.50) | CYP1A2CYP2A6 | |
| SCHEMBL4402445 | 0.77 | CYP2A6 (0.34) | CYP1A2CYP2A6 | |
| SCHEMBL16223776 | 0.77 | ALDH1A1 (0.36) | — | |
| SCHEMBL4401093 | 0.77 | CYP2A6 (0.34) | CYP2A6L3MBTL1 | |
| SCHEMBL3824244 | 0.74 | KDM4E (0.47) | CYP2A6NPC1 | |
| SCHEMBL4409411 | 0.74 | — | — | |
| SCHEMBL10321126 | 0.73 | CYP1A2 (0.41) | CYP1A2CYP2A6CASP3SENP7NPC1 | |
| SCHEMBL10321332 | 0.72 | MAPT (0.35) | — | |
| SCHEMBL4399735 | 0.72 | PDGFRB (0.56) | CYP1A2CYP2A6L3MBTL1NPC1 | |
| SCHEMBL10321514 | 0.71 | CYP17A1 (0.37) | L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817309-B1 | ACETAMIDE COMPOUNDS AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-12-23 | — | — | EP | claimed |
| EP-2970189-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9365545-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160046579-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC | 2016-02-18 | — | — | US | disclosed |
| EP-2970189-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Agios Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150336931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
| US-9108921-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014139325-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139144-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046579-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | CYP1A2 2109/4885CYP2A6 2539/4885L3MBTL1 2716/4885 |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | CYP1A2 2191/4885CYP2A6 2510/4885L3MBTL1 2619/4885 |
| US-20150336931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | CYP1A2 2191/4885CYP2A6 2510/4885L3MBTL1 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.